Compare Ginkgo Bioworks Holdings Inc (DNA) vs Google Inc (GOOG) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Alphabet (GOOG) trades at $350.02, up 0.76% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 32.8% net margins and consistent earnings beats, though significant capital expenditures have led to negative free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target, representing 24% upside potential from current levels.

The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors face risks from escalating capital spending, regulatory scrutiny, and multiple class-action lawsuits. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, supported by robust cash flow generation and expanding cloud revenue streams.